Patents by Inventor Julia Ashworth-Sharpe

Julia Ashworth-Sharpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018174
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: August 11, 2023
    Publication date: January 18, 2024
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11780863
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: October 10, 2023
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11740233
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 29, 2023
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Christopher Bieniarz, Michael Farrell, Donald D. Johnson, Jerome W. Kosmeder, Adrian E. Murillo, Chol Steven Yun, Zhanna Zhilina
  • Patent number: 11365210
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: June 21, 2022
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11359185
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jerome W Kosmeder, Mark Lefever, Casey A Kernag, Julia Ashworth-Sharpe, Jennifer Wong
  • Publication number: 20220041633
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Publication number: 20210341466
    Abstract: Disclosed herein are novel chromogenic conjugates, the conjugates comprising at least two detectable moieties.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 4, 2021
    Inventors: Julia Ashworth-Sharpe, Brian D. Kelly, Mark Lefever, Nathan W. Polaske
  • Patent number: 11143648
    Abstract: Disclosed herein are novel chromogenic conjugates, the conjugates comprising at least two detectable moieties.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 12, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Brian D. Kelly, Mark Lefever, Nathan W. Polaske
  • Publication number: 20210055285
    Abstract: Disclosed herein are novel chromogenic conjugates, the conjugates comprising at least two detectable moieties.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 25, 2021
    Inventors: Julia Ashworth-Sharpe, Brian D. Kelly, Mark Lefever, Nathan W. Polaske
  • Publication number: 20190187130
    Abstract: Disclosed herein are novel chromogenic conjugates, the conjugates comprising at least two detectable moieties.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 20, 2019
    Inventors: Julia Ashworth-Sharpe, Brian D. Kelly, Mark Lefever, Nathan W. Polaske
  • Publication number: 20190128893
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 2, 2019
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Publication number: 20190127405
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 2, 2019
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 10168336
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 1, 2019
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Publication number: 20180372733
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Inventors: Julia Ashworth-Sharpe, Christopher Bieniarz, Michael Farrell, Donald D. Johnson, Jerome W. Kosmeder, Adrian E. Murillo, Chol Steven Yun, Zhanna Zhilina
  • Patent number: 10031134
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 24, 2018
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Publication number: 20170131271
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Application
    Filed: September 12, 2016
    Publication date: May 11, 2017
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Publication number: 20170089911
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 30, 2017
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 9448231
    Abstract: Embodiments of a system, method, and kit for visualizing a nucleus are disclosed. A tissue sample is pretreated with a protease to permeabilize the nucleus, and then incubated with a nanoparticle/DNA-binding moiety conjugate. The DNA-binding moiety includes at least one DNA-binding molecule. The conjugate binds to DNA within the nucleus, and the nanoparticle is visualized, thereby visualizing the nucleus. Computer and image analysis techniques are used to evaluate nuclear features such as chromosomal distribution, ploidy, shape, size, texture features, and/or contextual features. The method may be used in combination with other multiplexed tests on the tissue sample, including fluorescence in situ hybridization. Kits for performing the method include a protease enzyme composition, a nanoparticle/DNA-binding moiety conjugate, and a reaction buffer.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: September 20, 2016
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Chol Steven Yun, Brian Daniel Kelly, Julia Ashworth-Sharpe, Christopher A. Bieniarz, Pascal Bamford, Adrian E. Murillo
  • Patent number: 9442107
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: September 13, 2016
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Publication number: 20160195540
    Abstract: A method is disclosed for making a conjugate of two molecules using a hydrazide thiol linker. In a particular working embodiment, an Fc-specific antibody-enzyme conjugate is made using the method and demonstrated to provide exceptional staining sensitivity and specificity in immunohistochemical and in situ hybridization assays.
    Type: Application
    Filed: February 24, 2016
    Publication date: July 7, 2016
    Inventors: Christopher Bieniarz, Jerome W. Kosmeder, Mark Lefever, Casey A. Kernag, Julia Ashworth-Sharpe